Selected research
Industry Growth & Trends
Global Antifibrotic Drug Industry Growth and Trends Forecast to 2032
Market perspective
The global Antifibrotic Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Antifibrotic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Antifibrotic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Antifibrotic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Antifibrotic Drug include Accord Healthcare, Amneal Pharmaceuticals, Apotex, Beacon Pharma, Boehringer Ingelheim, Eskayef Pharmaceuticals, ScieGen Pharmaceuticals, Gyre Pharmaceuticals and Kawin, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Antifibrotic Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Antifibrotic Drug market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Antifibrotic Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Antifibrotic Drug.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading manufacturers in the global Antifibrotic Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Antifibrotic Drug Market by Company
Accord Healthcare
Amneal Pharmaceuticals
Apotex
Beacon Pharma
Boehringer Ingelheim
Eskayef Pharmaceuticals
ScieGen Pharmaceuticals
Gyre Pharmaceuticals
Kawin
Roche
Qilu Pharmaceutical
PuraCap
Sandoz
CSPC Pharmaceutical Group
Kelun Pharmaceutical
Teva
Antifibrotic Drug Segment by Type
Nintedanib
Pirfenidone
Antifibrotic Drug Segment by Application
Hospital and Clinic
Retail Pharmacies
Other
Antifibrotic Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antifibrotic Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antifibrotic Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antifibrotic Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antifibrotic Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Antifibrotic Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Nintedanib
- Pirfenidone
Applications
- Hospital and Clinic
- Retail Pharmacies
- Other
Companies covered
- Accord Healthcare
- Amneal Pharmaceuticals
- Apotex
- Beacon Pharma
- Boehringer Ingelheim
- Eskayef Pharmaceuticals
- ScieGen Pharmaceuticals
- Gyre Pharmaceuticals
- Kawin
- Roche
- Qilu Pharmaceutical
- PuraCap
- Sandoz
- CSPC Pharmaceutical Group
- Kelun Pharmaceutical
- Teva
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Antifibrotic Drug Market Size Estimates and Forecasts (2021-2032)
- 1.2.2 Global Antifibrotic Drug Sales Estimates and Forecasts (2021-2032)
- 1.3 Antifibrotic Drug Market by Type
- 1.3.1 Nintedanib
- 1.3.2 Pirfenidone
- 1.4 Global Antifibrotic Drug Market Size by Type
- 1.4.1 Global Antifibrotic Drug Market Size Overview by Type (2021-2032)
- 1.4.2 Global Antifibrotic Drug Historic Market Size Review by Type (2021-2026)
- 1.4.3 Global Antifibrotic Drug Forecasted Market Size by Type (2027-2032)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America Antifibrotic Drug Sales Breakdown by Type (2021-2026)
- 1.5.2 Europe Antifibrotic Drug Sales Breakdown by Type (2021-2026)
- 1.5.3 Asia-Pacific Antifibrotic Drug Sales Breakdown by Type (2021-2026)
- 1.5.4 South America Antifibrotic Drug Sales Breakdown by Type (2021-2026)
- 1.5.5 Middle East and Africa Antifibrotic Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
- 2.1 Antifibrotic Drug Industry Trends
- 2.2 Antifibrotic Drug Industry Drivers
- 2.3 Antifibrotic Drug Industry Opportunities and Challenges
- 2.4 Antifibrotic Drug Industry Restraints
3 Market Competitive Landscape by Company
- 3.1 Global Top Players by Antifibrotic Drug Revenue (2021-2026)
- 3.2 Global Top Players by Antifibrotic Drug Sales (2021-2026)
- 3.3 Global Top Players by Antifibrotic Drug Price (2021-2026)
- 3.4 Global Antifibrotic Drug Industry Company Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Antifibrotic Drug Major Company Production Sites & Headquarters
- 3.6 Global Antifibrotic Drug Company, Product Type & Application
- 3.7 Global Antifibrotic Drug Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Antifibrotic Drug Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Antifibrotic Drug Players Market Share by Revenue in 2025
- 3.8.3 2025 Antifibrotic Drug Tier 1, Tier 2, and Tier 3
4 Antifibrotic Drug Regional Status and Outlook
- 4.1 Global Antifibrotic Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
- 4.2 Global Antifibrotic Drug Historic Market Size by Region
- 4.2.1 Global Antifibrotic Drug Sales in Volume by Region (2021-2026)
- 4.2.2 Global Antifibrotic Drug Sales in Value by Region (2021-2026)
- 4.2.3 Global Antifibrotic Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
- 4.3 Global Antifibrotic Drug Forecasted Market Size by Region
- 4.3.1 Global Antifibrotic Drug Sales in Volume by Region (2027-2032)
- 4.3.2 Global Antifibrotic Drug Sales in Value by Region (2027-2032)
- 4.3.3 Global Antifibrotic Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Antifibrotic Drug by Application
- 5.1 Antifibrotic Drug Market by Application
- 5.1.1 Hospital and Clinic
- 5.1.2 Retail Pharmacies
- 5.1.3 Other
- 5.2 Global Antifibrotic Drug Market Size by Application
- 5.2.1 Global Antifibrotic Drug Market Size Overview by Application (2021-2032)
- 5.2.2 Global Antifibrotic Drug Historic Market Size Review by Application (2021-2026)
- 5.2.3 Global Antifibrotic Drug Forecasted Market Size by Application (2027-2032)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America Antifibrotic Drug Sales Breakdown by Application (2021-2026)
- 5.3.2 Europe Antifibrotic Drug Sales Breakdown by Application (2021-2026)
- 5.3.3 Asia-Pacific Antifibrotic Drug Sales Breakdown by Application (2021-2026)
- 5.3.4 South America Antifibrotic Drug Sales Breakdown by Application (2021-2026)
- 5.3.5 Middle East and Africa Antifibrotic Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
- 6.1 Accord Healthcare
- 6.1.1 Accord Healthcare Company Information
- 6.1.2 Accord Healthcare Business Overview
- 6.1.3 Accord Healthcare Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.1.4 Accord Healthcare Antifibrotic Drug Product Portfolio
- 6.1.5 Accord Healthcare Recent Developments
- 6.2 Amneal Pharmaceuticals
- 6.2.1 Amneal Pharmaceuticals Company Information
- 6.2.2 Amneal Pharmaceuticals Business Overview
- 6.2.3 Amneal Pharmaceuticals Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.2.4 Amneal Pharmaceuticals Antifibrotic Drug Product Portfolio
- 6.2.5 Amneal Pharmaceuticals Recent Developments
- 6.3 Apotex
- 6.3.1 Apotex Company Information
- 6.3.2 Apotex Business Overview
- 6.3.3 Apotex Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.3.4 Apotex Antifibrotic Drug Product Portfolio
- 6.3.5 Apotex Recent Developments
- 6.4 Beacon Pharma
- 6.4.1 Beacon Pharma Company Information
- 6.4.2 Beacon Pharma Business Overview
- 6.4.3 Beacon Pharma Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.4.4 Beacon Pharma Antifibrotic Drug Product Portfolio
- 6.4.5 Beacon Pharma Recent Developments
- 6.5 Boehringer Ingelheim
- 6.5.1 Boehringer Ingelheim Company Information
- 6.5.2 Boehringer Ingelheim Business Overview
- 6.5.3 Boehringer Ingelheim Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.5.4 Boehringer Ingelheim Antifibrotic Drug Product Portfolio
- 6.5.5 Boehringer Ingelheim Recent Developments
- 6.6 Eskayef Pharmaceuticals
- 6.6.1 Eskayef Pharmaceuticals Company Information
- 6.6.2 Eskayef Pharmaceuticals Business Overview
- 6.6.3 Eskayef Pharmaceuticals Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.6.4 Eskayef Pharmaceuticals Antifibrotic Drug Product Portfolio
- 6.6.5 Eskayef Pharmaceuticals Recent Developments
- 6.7 ScieGen Pharmaceuticals
- 6.7.1 ScieGen Pharmaceuticals Company Information
- 6.7.2 ScieGen Pharmaceuticals Business Overview
- 6.7.3 ScieGen Pharmaceuticals Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.7.4 ScieGen Pharmaceuticals Antifibrotic Drug Product Portfolio
- 6.7.5 ScieGen Pharmaceuticals Recent Developments
- 6.8 Gyre Pharmaceuticals
- 6.8.1 Gyre Pharmaceuticals Company Information
- 6.8.2 Gyre Pharmaceuticals Business Overview
- 6.8.3 Gyre Pharmaceuticals Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.8.4 Gyre Pharmaceuticals Antifibrotic Drug Product Portfolio
- 6.8.5 Gyre Pharmaceuticals Recent Developments
- 6.9 Kawin
- 6.9.1 Kawin Company Information
- 6.9.2 Kawin Business Overview
- 6.9.3 Kawin Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.9.4 Kawin Antifibrotic Drug Product Portfolio
- 6.9.5 Kawin Recent Developments
- 6.10 Roche
- 6.10.1 Roche Company Information
- 6.10.2 Roche Business Overview
- 6.10.3 Roche Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.10.4 Roche Antifibrotic Drug Product Portfolio
- 6.10.5 Roche Recent Developments
- 6.11 Qilu Pharmaceutical
- 6.11.1 Qilu Pharmaceutical Company Information
- 6.11.2 Qilu Pharmaceutical Business Overview
- 6.11.3 Qilu Pharmaceutical Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.11.4 Qilu Pharmaceutical Antifibrotic Drug Product Portfolio
- 6.11.5 Qilu Pharmaceutical Recent Developments
- 6.12 PuraCap
- 6.12.1 PuraCap Company Information
- 6.12.2 PuraCap Business Overview
- 6.12.3 PuraCap Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.12.4 PuraCap Antifibrotic Drug Product Portfolio
- 6.12.5 PuraCap Recent Developments
- 6.13 Sandoz
- 6.13.1 Sandoz Company Information
- 6.13.2 Sandoz Business Overview
- 6.13.3 Sandoz Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.13.4 Sandoz Antifibrotic Drug Product Portfolio
- 6.13.5 Sandoz Recent Developments
- 6.14 CSPC Pharmaceutical Group
- 6.14.1 CSPC Pharmaceutical Group Company Information
- 6.14.2 CSPC Pharmaceutical Group Business Overview
- 6.14.3 CSPC Pharmaceutical Group Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.14.4 CSPC Pharmaceutical Group Antifibrotic Drug Product Portfolio
- 6.14.5 CSPC Pharmaceutical Group Recent Developments
- 6.15 Kelun Pharmaceutical
- 6.15.1 Kelun Pharmaceutical Company Information
- 6.15.2 Kelun Pharmaceutical Business Overview
- 6.15.3 Kelun Pharmaceutical Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.15.4 Kelun Pharmaceutical Antifibrotic Drug Product Portfolio
- 6.15.5 Kelun Pharmaceutical Recent Developments
- 6.16 Teva
- 6.16.1 Teva Company Information
- 6.16.2 Teva Business Overview
- 6.16.3 Teva Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.16.4 Teva Antifibrotic Drug Product Portfolio
- 6.16.5 Teva Recent Developments
7 North America by Country
- 7.1 North America Antifibrotic Drug Sales by Country
- 7.1.1 North America Antifibrotic Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.1.2 North America Antifibrotic Drug Sales by Country (2021-2026)
- 7.1.3 North America Antifibrotic Drug Sales Forecast by Country (2027-2032)
- 7.2 North America Antifibrotic Drug Market Size by Country
- 7.2.1 North America Antifibrotic Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2.2 North America Antifibrotic Drug Market Size by Country (2021-2026)
- 7.2.3 North America Antifibrotic Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
- 8.1 Europe Antifibrotic Drug Sales by Country
- 8.1.1 Europe Antifibrotic Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.1.2 Europe Antifibrotic Drug Sales by Country (2021-2026)
- 8.1.3 Europe Antifibrotic Drug Sales Forecast by Country (2027-2032)
- 8.2 Europe Antifibrotic Drug Market Size by Country
- 8.2.1 Europe Antifibrotic Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2.2 Europe Antifibrotic Drug Market Size by Country (2021-2026)
- 8.2.3 Europe Antifibrotic Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
- 9.1 Asia-Pacific Antifibrotic Drug Sales by Country
- 9.1.1 Asia-Pacific Antifibrotic Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.1.2 Asia-Pacific Antifibrotic Drug Sales by Country (2021-2026)
- 9.1.3 Asia-Pacific Antifibrotic Drug Sales Forecast by Country (2027-2032)
- 9.2 Asia-Pacific Antifibrotic Drug Market Size by Country
- 9.2.1 Asia-Pacific Antifibrotic Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2.2 Asia-Pacific Antifibrotic Drug Market Size by Country (2021-2026)
- 9.2.3 Asia-Pacific Antifibrotic Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
- 10.1 South America Antifibrotic Drug Sales by Country
- 10.1.1 South America Antifibrotic Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.1.2 South America Antifibrotic Drug Sales by Country (2021-2026)
- 10.1.3 South America Antifibrotic Drug Sales Forecast by Country (2027-2032)
- 10.2 South America Antifibrotic Drug Market Size by Country
- 10.2.1 South America Antifibrotic Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2.2 South America Antifibrotic Drug Market Size by Country (2021-2026)
- 10.2.3 South America Antifibrotic Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
- 11.1 Middle East and Africa Antifibrotic Drug Sales by Country
- 11.1.1 Middle East and Africa Antifibrotic Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.1.2 Middle East and Africa Antifibrotic Drug Sales by Country (2021-2026)
- 11.1.3 Middle East and Africa Antifibrotic Drug Sales Forecast by Country (2027-2032)
- 11.2 Middle East and Africa Antifibrotic Drug Market Size by Country
- 11.2.1 Middle East and Africa Antifibrotic Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2.2 Middle East and Africa Antifibrotic Drug Market Size by Country (2021-2026)
- 11.2.3 Middle East and Africa Antifibrotic Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
- 12.1 Antifibrotic Drug Value Chain Analysis
- 12.1.1 Antifibrotic Drug Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 Antifibrotic Drug Production Mode & Process
- 12.2 Antifibrotic Drug Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 Antifibrotic Drug Distributors
- 12.2.3 Antifibrotic Drug Customers
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst